ADR's of Edap TMS (EDAP +17.8%) jump today on the back of a postitive article in Seeking Alpha, calling it the 'holy grail' in the fight against prostate cancer. Its recent disclosure of test data on its Ablatherm-HIFU - which uses High-Intensity Focused Ultrasound to eviscerate localized prostate cancer - shows it's testing progress has advanced well beyond the stage of laboratories and mice, and is highly likely to receive FDA approval.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs